Case and Research Letter
Dupilumab to Treat Chronic Palmoplantar Eczema: A Retrospective Multicenter Cohort Study
Tratamiento del eccema crónico palmo-plantar con dupilumab: estudio de cohortes retrospectivo multicéntrico
Read
1856
Timeswas read the article
491
Total PDF
1365
Total HTML
Share statistics
array:24 [ "pii" => "S0001731024003508" "issn" => "00017310" "doi" => "10.1016/j.ad.2024.04.010" "estado" => "S300" "fechaPublicacion" => "2024-06-01" "aid" => "3944" "copyright" => "AEDV" "copyrightAnyo" => "2024" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2024;115:T628-T631" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "itemSiguiente" => array:18 [ "pii" => "S000173102400142X" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.10.047" "estado" => "S300" "fechaPublicacion" => "2024-06-01" "aid" => "3854" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2024;115:632-5" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICO-CLÍNICA</span>" "titulo" => "Estudio observacional retrospectivo de 35 casos de lentigo maligno y melanoma lentiginoso acral tratados quirúrgicamente mediante una técnica de espagueti modificada" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "632" "paginaFinal" => "635" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Thirty-Five-Case Retrospective Observational Study of Lentigo Maligna and Acral Lentiginous Melanoma Surgically Treated With a Modified Spaghetti Technique" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figura 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 912 "Ancho" => 1674 "Tamanyo" => 167198 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">A) Espagueti incluido en su totalidad en macrobloque; B) comparación con el convencional. C) Corte histológico del espagueti en un macroporta; D) comparación con el convencional.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "E. Samaniego González, M.A. González Morán, V. Onecha Vallejo, A.I. de la Hera Magallanes, M. Navedo de las Heras, M.Á. Rodríguez Prieto" "autores" => array:6 [ 0 => array:2 [ "nombre" => "E." "apellidos" => "Samaniego González" ] 1 => array:2 [ "nombre" => "M.A." "apellidos" => "González Morán" ] 2 => array:2 [ "nombre" => "V." "apellidos" => "Onecha Vallejo" ] 3 => array:2 [ "nombre" => "A.I." "apellidos" => "de la Hera Magallanes" ] 4 => array:2 [ "nombre" => "M." "apellidos" => "Navedo de las Heras" ] 5 => array:2 [ "nombre" => "M.Á." "apellidos" => "Rodríguez Prieto" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S000173102400142X?idApp=UINPBA000044" "url" => "/00017310/0000011500000006/v1_202406021150/S000173102400142X/v1_202406021150/es/main.assets" ] "itemAnterior" => array:18 [ "pii" => "S0001731024001418" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.12.006" "estado" => "S300" "fechaPublicacion" => "2024-06-01" "aid" => "3853" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2024;115:628-31" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICO-CLÍNICA</span>" "titulo" => "Tratamiento del eccema crónico palmo-plantar con dupilumab: estudio de cohortes retrospectivo multicéntrico" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "628" "paginaFinal" => "631" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Dupilumab to Treat Chronic Palmoplantar Eczema: A Retrospective Multicenter Cohort Study" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 745 "Ancho" => 1207 "Tamanyo" => 144809 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Eccema dishidrótico en plantas de los pies y pulpejos de los dedos con mejoría completa a los dos meses de tratamiento con dupilumab.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Magdaleno-Tapial, A. Torrijos Aguilar, V. González-Delgado, P. Hernández-Bel" "autores" => array:4 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Magdaleno-Tapial" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Torrijos Aguilar" ] 2 => array:2 [ "nombre" => "V." "apellidos" => "González-Delgado" ] 3 => array:2 [ "nombre" => "P." "apellidos" => "Hernández-Bel" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024001418?idApp=UINPBA000044" "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024001418/v1_202406021150/es/main.assets" ] "asociados" => array:1 [ 0 => array:18 [ "pii" => "S0001731024001418" "issn" => "00017310" "doi" => "10.1016/j.ad.2023.12.006" "estado" => "S300" "fechaPublicacion" => "2024-06-01" "aid" => "3853" "copyright" => "AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2024;115:628-31" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICO-CLÍNICA</span>" "titulo" => "Tratamiento del eccema crónico palmo-plantar con dupilumab: estudio de cohortes retrospectivo multicéntrico" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "628" "paginaFinal" => "631" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Dupilumab to Treat Chronic Palmoplantar Eczema: A Retrospective Multicenter Cohort Study" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 745 "Ancho" => 1207 "Tamanyo" => 144809 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Eccema dishidrótico en plantas de los pies y pulpejos de los dedos con mejoría completa a los dos meses de tratamiento con dupilumab.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "J. Magdaleno-Tapial, A. Torrijos Aguilar, V. González-Delgado, P. Hernández-Bel" "autores" => array:4 [ 0 => array:2 [ "nombre" => "J." "apellidos" => "Magdaleno-Tapial" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Torrijos Aguilar" ] 2 => array:2 [ "nombre" => "V." "apellidos" => "González-Delgado" ] 3 => array:2 [ "nombre" => "P." "apellidos" => "Hernández-Bel" ] ] ] ] ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024001418?idApp=UINPBA000044" "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024001418/v1_202406021150/es/main.assets" ] ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letter</span>" "titulo" => " Dupilumab to Treat Chronic Palmoplantar Eczema: A Retrospective Multicenter Cohort Study" "tieneTextoCompleto" => true "saludo" => "<span class="elsevierStyleItalic">To the Editor,</span>" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "T628" "paginaFinal" => "T631" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "J. Magdaleno-Tapial, A. Torrijos Aguilar, V. González-Delgado, P. Hernández-Bel" "autores" => array:4 [ 0 => array:4 [ "nombre" => "J." "apellidos" => "Magdaleno-Tapial" "email" => array:1 [ 0 => "jormagta@gmail.com" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "A." "apellidos" => "Torrijos Aguilar" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "V." "apellidos" => "González-Delgado" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] 3 => array:3 [ "nombre" => "P." "apellidos" => "Hernández-Bel" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital General Universitario de Valencia, Valencia, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Arnau de Vilanova de Valencia, Valencia, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Clínico Universitario de Valencia, Valencia, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Tratamiento del eccema crónico palmo-plantar con dupilumab: estudio de cohortes retrospectivo multicéntrico" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 579 "Ancho" => 937 "Tamanyo" => 78912 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Hyperkeratotic eczema on the soles of the feet with improvement after 6 months on dupilumab.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Chronic hand and/or foot eczema (CHFE) is a chronic skin disease that can have a significant impact on the patients’ quality of life.<a class="elsevierStyleCrossRef" href="#bib0045"><span class="elsevierStyleSup">1</span></a> Currently, alitretinoin is the only systemic drug authorized for this indication in the European Union.<a class="elsevierStyleCrossRef" href="#bib0050"><span class="elsevierStyleSup">2</span></a> In recent years, dupilumab, a human monoclonal antibody targeting interleukin-4 and interleukin-13, has proven its efficacy treating patients with atopic dermatitis (AD), and its various phenotypes or related disorders such as nodular prurigo or CHFE.</p><p id="par0010" class="elsevierStylePara elsevierViewall">This study describes the real-world experience of dupilumab in patients with CHFE. We designed a multicenter, retrospective, observational study with adult patients diagnosed with CHFE on dupilumab, with or without AD lesions in other anatomical regions. Cases of relevant allergic sensitization responsible for the patient's chronic eczema were excluded. Treatment response was assessed objectively (partial improvement if a 75% improvement was achieved or total if lesions were completely gone) and through patient-reported outcomes (PRO) at each clinical visit, using the Visual Analog Scale (VAS) for itch and the Dermatology Life Quality Index (DLQI).</p><p id="par0015" class="elsevierStylePara elsevierViewall">We enrolled a total of 11 patients (9 women [82%] and 2 men [18%]), with a median age of 40 years (range, 28-75). Their clinical-epidemiological characteristics are shown in <a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>. Five patients (45%) had a past medical history of AD onset in childhood (2) or adulthood (3). In 6 patients (54%) only the palms of their hands and/or the soles of their feet were compromised. Lesions in these locations had a mean 4-year history (range, 6 months to 20 years), and 2 patients exhibited the dyshidrotic eczema phenotype vs the remaining 9 who exhibited the hyperkeratotic phenotype. Five patients (45%) had been treated with oral retinoids, 3 of them (27%) with methotrexate, and 2 (18%) with cyclosporine. Two (18%) had received previous treatment with drugs approved for use in psoriasis such as apremilast, brodalumab, or ixekizumab. The median baseline DLQI was 16 (range, 13-28), and the median itch VAS was 9 (range, 8-10). The median follow-up was 68 weeks. All patients reported lesion improvement within the first 4 weeks of treatment, and 8 of them (72%) achieved complete lesion improvement within the first 4 months of therapy (<a class="elsevierStyleCrossRefs" href="#fig0005">Figures 1 and 2</a>). The median DLQI on week 16 was 2 (range, 0-16), representing a 78.3% reduction vs baseline. Treatment was up-titrated every 10 days at the follow-up in 1 patient due to partial response, while another patient had to discontinue treatment on week 16 due to inefficacy. The remaining patients (80%) continued with the drug. One patient down-titrated every 21 days. No adverse events were reported.</p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0020" class="elsevierStylePara elsevierViewall">The efficacy of dupilumab in palmoplantar involvement has been reported in several case series. Osterhaven et al. presented a prospective, observational study of 47 patients, 74.5% of whom exhibited chronic fissured eczema and 25.5%, vesicular eczema treated with dupilumab, 60% of whom improved—75% compared to baseline—with no differences reported between both clinical subtypes. Additionally, improvement was observed within the first 4 weeks of treatment becoming substantial improvement within the first 16 weeks,<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">3</span></a> which are data consistent with those presented in our study. In our patients, the median DLQI reduction was almost 80%, which is similar to what the Dutch series reported (70%). Voorberg et al. published the results of a prospective analysis of 72 patients with CHFE with or without AD treated with dupilumab and a 52-week follow-up, achieving a 75% improvement in the Hand Eczema Severity Index (HECSI-75) and HECSI-90 in 87.1% and 62.9%, respectively, with progressive clinical improvement from week 16 to week 52 and an improved quality of life.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">4</span></a> Finally, Lee et al. retrospectively compared the response to dupilumab between patients with AD and hand involvement (38/66) and those with AD only without hand involvement (28/66), and found no significant differences between both subgroups.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">5</span></a> Recently, Olesen et al. reported their experience with 19 patients with chronic hand eczema, and confirmed improvement in 73.7% of them.<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">6</span></a> Of note in this latter study is the use of biologic drugs approved for psoriasis, as it is the case of 2 of the 11 patients from our series, which reveals the diagnostic challenge posed by hyperkeratotic hand and/or foot eczema without any other suggestive cutaneous lesions of AD or psoriasis.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">7</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The experience reported has led to the phase 3 randomized double-blind LIBERTY-AD-HAFT trial <a href="ctgov:NCT04417894">NCT04417894</a> that is evaluating the safety and efficacy profile of dupilumab in adults and adolescents with CHFE. A total of 133 patients were randomized on a 1:1 ratio to receive dupilumab vs placebo, concluding that dupilumab improved the signs, symptoms, and quality of life of patients with hand and foot eczema measured by Investigator Global Assessment (IGA) 0/1, a <span class="elsevierStyleUnderline">></span> 4 point improvement in HECSI, itch VAS, or quality of life scale.<a class="elsevierStyleCrossRef" href="#bib0080"><span class="elsevierStyleSup">8</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">Limitations of our analysis include its small sample size and absence of some data typical of a retrospective study, which would have given greater robustness to the results. On the other hand, The HECSI was not measured, nor were other PROs such as pain, stinging, or specific quality of life scales.</p><p id="par0035" class="elsevierStylePara elsevierViewall">In conclusion, in our experience, patients with CHFE show both clinical and subjective improvement early after initiating treatment with dupilumab. Longer-term follow-ups of patients and more cases supporting the use of this drug for the treatment of these conditions are necessary.</p><span id="sec0005" class="elsevierStyleSection elsevierViewall"><span class="elsevierStyleSectionTitle" id="sect0005">Conflicts of interest</span><p id="par0040" class="elsevierStylePara elsevierViewall">None declared.</p></span></span>" "textoCompletoSecciones" => array:1 [ "secciones" => array:2 [ 0 => array:2 [ "identificador" => "sec0005" "titulo" => "Conflicts of interest" ] 1 => array:1 [ "titulo" => "References" ] ] ] "pdfFichero" => "main.pdf" "tienePdf" => true "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 559 "Ancho" => 906 "Tamanyo" => 94409 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Dyshidrotic eczema on the soles of the feet and toe pulp with complete improvement after 2 months on dupilumab.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 579 "Ancho" => 937 "Tamanyo" => 78912 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Hyperkeratotic eczema on the soles of the feet with improvement after 6 months on dupilumab.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0020" class="elsevierStyleSimplePara elsevierViewall">ACD, allergic contact dermatitis; AD, atopic dermatitis; BSA, body surface area; DLQI, Dermatology Life Quality Index; EASI, Eczema Area and Severity Index; PRO, patient reported outcomes.</p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Sex, age \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Previous atopic history \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">History of palmar-plantar lesions \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Distribution and lesion phenotype \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Previous treatments \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Baseline PROs \t\t\t\t\t\t\n \t\t\t\t\t\t</th><th class="td" title="\n \t\t\t\t\ttable-head\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t" scope="col" style="border-bottom: 2px solid black">Response to dupilumab \t\t\t\t\t\t\n \t\t\t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman, 40 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Childhood ADAllergic sensitization to nickel and cobalt \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hyperkeratotic plantar eczema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitors, AntihistaminesOral corticosteroidsAlitretinoinAcitretin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 28Itch 10/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">75% improvement at 1 month, at 2 months itch reduced to 2/10 and DLQI to 7/30, escalated every 10 days. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman, 28 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Nickel sensitization \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hyperkeratotic eczema on 30% of both hands and 40% of both feet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitors, AntihistaminesAcitretinMethotrexateApremilastBrodalumab, Cyclosporine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 16Itch 9/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Whitened after 1 month of treatment \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Man, 75 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Allergic sensitization to fragrance mix I, thiomersal, and balsam of Peru \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">10 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hyperkeratotic eczema on palms and soles \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitors, AntihistaminesAlitretinoin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 13Itch 8/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Whitened after 2 months of treatment \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman, 67 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">20 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hyperkeratotic eczema on palms and soles, dyshidrotic eczema on hands \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitors AntihistaminesAcitretin \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 23Itch 9/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Slight improvement in fissures, discontinued at 16 weeks due to inefficacy \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman, 33 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Allergic asthma, sensitization to dust mites and pellitory Perennial rhinitis \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">6 months \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dyshidrotic eczema on soles of feet and hands \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitorsOral corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 19Itch 10/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Whitened after 2 months of treatment (<a class="elsevierStyleCrossRef" href="#fig0005">figure 1</a>) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman, 36 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adult ADNickel sensitization \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Plantar hyperkeratotic eczema, atopic eczema lesions on trunk, legs, and arms \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitors, AntihistaminesOral corticosteroids, Methotrexate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 15Itch 9/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">50% improvement at 1 month, completely whitened at 6 months, down-titration every 21 days (<a class="elsevierStyleCrossRef" href="#fig0010">figure 2</a>) \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman, 32 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Childhood AD \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hyperkeratotic eczema on palms (and dorsum) and flexural \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitorsOral corticosteroidsMethotrexate \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Itch/sleep: 10/10 DLQI 15 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 1 on week 4DLQI 0 and EASI 0 on weeks 16, 52, and 104 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman, 56 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adult ADACD to rubber (nurse) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">3 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Palmar hyperkeratotic eczema, Subacute eczema on back and flexures \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitorsOral corticosteroidsCyclosporine \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">EASI 18BSA 33%DLQI 19, Itch/sleep: 10/8 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 0 and itch 2 on week 4DLQI 0 and itch 1 on week 16Whitened since week 16 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Man, 71 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Adult ADACD to perfumes (isoeugenol, oil of cloves) \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">7 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hyperkeratotic eczema on handsEczema on trunk and limbs \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitorsOral corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Itch/sleep: 8/6, DLQI 15EASI 21, BSA 25% \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Itch 0 on week 4Whitened since week 16 with DLQI 2 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman, 39 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">2 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Dyshidrotic eczema \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcineurin inhibitorsOral corticosteroids \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 22Itch 10/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Itch 1 on week 4Whitened from week 16 with DLQI 0 \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t ; entry_with_role_rowhead " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Woman, 53 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">None \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">4 years \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Hyperkeratotic eczema on hands and feet \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">Topical corticosteroids and calcipotriol, AcitretinIxekizumab \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">DLQI 16Itch 9/10 \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="\n \t\t\t\t\ttable-entry\n \t\t\t\t " align="left" valign="\n \t\t\t\t\ttop\n \t\t\t\t">75% improvement at 1 month, no lesions at 2 months, itch 1/10 and DLQI 2/30 \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab3555929.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Clinical-epidemiological characteristics of patients with chronic hand and/or foot eczema treated with dupilumab.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:8 [ 0 => array:3 [ "identificador" => "bib0045" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Tolerability and efficacy of a medical device repairing emollient cream in adults with chronic hand dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "M.D. Thouvenin" 1 => "A. Bacquey" 2 => "T. Nocera" 3 => "A.B. Rossi" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jocd.12764" "Revista" => array:6 [ "tituloSerie" => "J Cosmet Dermatol." "fecha" => "2018" "volumen" => "17" "paginaInicial" => "1158" "paginaFinal" => "1164" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30195267" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0050" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Guidelines for diagnosis, prevention, and treatment of hand eczema" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "J.P. Thyssen" 1 => "M.L.A. Schuttelaar" 2 => "J.H. Alfonso" 3 => "K.E. Andersen" 4 => "I. Angelova-Fischer" 5 => "B.W.M. Arents" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/cod.14035" "Revista" => array:6 [ "tituloSerie" => "Contact Dermatitis." "fecha" => "2022" "volumen" => "86" "paginaInicial" => "357" "paginaFinal" => "378" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/34971008" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0055" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Effect of dupilumab on hand eczema in patients with atopic dermatitis: An observational study" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J.A.F. Oosterhaven" 1 => "A.N. Voorberg" 2 => "G.L.E. Romeijn" 3 => "M.S. de Bruin-Weller" 4 => "M.L.A. Schuttelaar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/1346-8138.14982" "Revista" => array:5 [ "tituloSerie" => "J Dermatol." "fecha" => "2019" "volumen" => "46" "paginaInicial" => "680" "paginaFinal" => "685" ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0060" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The long-term effect of dupilumab on chronic hand eczema in patients with moderate to severe atopic dermatitis-52 week results from the Dutch BioDay Registry" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "A.N. Voorberg" 1 => "G.L.E. Romeijn" 2 => "M.S. de Bruin-Weller" 3 => "M.L.A. Schuttelaar" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/cod.14104" "Revista" => array:6 [ "tituloSerie" => "Contact Dermatitis." "fecha" => "2022" "volumen" => "87" "paginaInicial" => "185" "paginaFinal" => "191" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/35279856" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0065" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "A Retrospective Review of Dupilumab for Hand Dermatitis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "N. Lee" 1 => "N. Chipalkatti" 2 => "P. Zancanaro" 3 => "C. Kachuk" 4 => "N. Dumont" 5 => "D. Rosmarin" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1159/000496481" "Revista" => array:6 [ "tituloSerie" => "Dermatology." "fecha" => "2019" "volumen" => "235" "paginaInicial" => "187" "paginaFinal" => "188" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/30726838" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0070" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Treatment of chronic hand eczema with dupilumab-A retrospective follow-up study" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "C.M. Olesen" 1 => "Y.T. Yüksel" 2 => "C. Zachariae" 3 => "T.T. Lund" 4 => "T. Agner" 5 => "T.S. Petersen" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1111/jdv.18805" "Revista" => array:6 [ "tituloSerie" => "J Eur Acad Dermatol Venereol." "fecha" => "2023" "volumen" => "37" "paginaInicial" => "e557" "paginaFinal" => "e559" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/36463422" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0075" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:6 [ 0 => "A. Al-Janabi" 1 => "A.C. Foulkes" 2 => "K. Mason" 3 => "C.H. Smith" 4 => "C.E.M. Griffiths" 5 => "R.B. Warren" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "J Eur Acad Dermatol Venereol." "fecha" => "2020" "volumen" => "34" "paginaInicial" => "1440" "paginaFinal" => "1448" ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0080" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "408 Dupilumab Treatment in Patients With Atopic Hand and Foot Dermatitis: Results From a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "E.L. Simpson" 1 => "J.I. Silverberg" 2 => "M. Worm" 3 => "G. Honari" 4 => "K. Masuda" 5 => "E. Sygula" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1093/bjd/ljad162.029" "Revista" => array:3 [ "tituloSerie" => "Br J Dermatol." "fecha" => "2023" "volumen" => "188" ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/00017310/0000011500000006/v1_202406021150/S0001731024003508/v1_202406021150/en/main.assets" "Apartado" => array:4 [ "identificador" => "6160" "tipo" => "SECCION" "es" => array:2 [ "titulo" => "Cartas científico-clínicas" "idiomaDefecto" => true ] "idiomaDefecto" => "es" ] "PDF" => "https://static.elsevier.es/multimedia/00017310/0000011500000006/v1_202406021150/S0001731024003508/v1_202406021150/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731024003508?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 23 | 13 | 36 |
| 2024 October | 148 | 73 | 221 |
| 2024 September | 145 | 46 | 191 |
| 2024 August | 193 | 75 | 268 |
| 2024 July | 152 | 62 | 214 |
| 2024 June | 309 | 77 | 386 |
| 2024 May | 309 | 99 | 408 |
| 2024 April | 86 | 46 | 132 |
